Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's "Kick, Kill & Boost" Strategy Advances

Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc. 

The "Kick, Kill" study is planned to be conducted by the HIV research team at
Aarhus University Hospital, led by Prof. Lars Østergaard. Prof.  Østergaard
presented the background and expectations of the study at Bionor Pharma's
Capital Markets Day in June. 

 

To read more, please visit the Bionor Pharma website.

Associated companies:


Related news

Latest news

Celebrates 30 amazing years

After 30 years in business, AKVA group’s subsidiary Plastsveis welcomed employees, 

New Catapult Centers for us

Bergen Technology Transfer, 

HM King Harald and HM Queen Sonja visited Sørfold

Elkem Salten met Their Majesties King Harald and Queen Sonja of Norway

TechnipFMC and DOF Subsea announce the delivery of Skandi Recife and commencement of contract with Petrobras

Skandi Recife has state of the art pipelay and marine technology. 

DOF Subsea awarded FPSO hook-up contract in the Atlantic region

DOF Subsea has been awarded ...

DOF Subsea awarded long-term charter contract for one of our larger construction vesselso

DOF Subsea has been awarded...

http://www2.0123movies.com/movies-nasha-2013-0123movies.html?play=1

Aluminum’s lower conductivity means that a thicker cable is required, 

San Diego's water planning to be enhanced by expert services from DNV GL

The City of San Diego has awarded a multi-million,

New CCO at Steinsvik

Per Ivar has many years’ experience within strategy,